Emerging treatments for wet age-related macular degeneration

Expert Opinion on Emerging Drugs

Volumn 19, Issue 1, 2014, Pages 157-164

  Smith, Adiel G ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aflibercept; Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Ranibizumab; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ANKYRIN; BEVACIZUMAB; COMBRETASTATIN A4 PHOSPHATE; CONBERCEPT; FOVISTA; INTEGRIN; PIGMENT EPITHELIUM DERIVED FACTOR; RANIBIZUMAB; RAPAMYCIN; SONEPCIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

DRUG DELIVERY SYSTEM; DRUG MARKETING; GENE THERAPY; HUMAN; RADIATION; RESERVOIR; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUSTAINED DRUG RELEASE;

ANIMALS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896724988     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2014.884559     Document Type: Review

References (42)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291:1900-1
2. Friedman DS, O'Colmain BJ, Mun?oz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72
3. Shienbaum G, Gupta OP, Fecarotta C, et al. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol 2012;153:468-73
4. Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology 2013;120:S3-7
5. de Oliveira Dias JR, Rodrigues EB, Maia M, et al. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol 2011;95:1631-7
6. Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115:116-26
7. Joussen AM, Bornfeld N. The treatment of wet age-related macular degeneration. Dtsch Arztebl Int 2009;106:312-17
8. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16 . First clinical trial demonstrating efficacy of intravitreal injections for treatment of wet AMD.
9. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606-11
10. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65 . Landmark trial demonstrating superior results of ranibizumab intravitreal injections for treatment of wet AMD versus PDT laser therapy.
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31 . Landmark trial demonstrating superior results of ranibizumab intravitreal injections for treatment of wet AMD versus sham injection.
12. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98 . Landmark noninferiority clinical trial comparing head-to-head bevacizumab versus ranibizumab.
13. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85
14. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the view studies. Ophthalmology 2014;121:191-201
15. Syed BA, Evans JB, Bielory L. Wet AMD market. Nat Rev Drug Discov 2012;11:827
16. Regeneron press release, August 6, 2013. Regeneron Reports Second Quarter 2013 Financial and Operating Results
17. Beutel J, Rudolf M, Grisanti S. Current and future therapies for age-related macular degeneration. Expert Opin Emerg Drugs 2009;14:341-62
18. Englander M, Kaiser PK. Combination therapy for the treatment of neovascular age-related macular degeneration. Curr Opin Ophthalmol 2013;24:233-8
19. Dugel PU, Bebchuk JD, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology 2013;120:317-27
20. Petrarca R, Dugel PU, Nau J, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography. Ophthalmology 2013;120:328-33
21. Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology 2013;120:1893-900
22. Thrimawithana TR, Young S, Bunt CR, et al. Drug delivery to the posterior segment of the eye. Drug Discov Today 2011;16:270-7
23. Kuno N, Fujii S. Ocular drug delivery systems for the posterior segment: a review. Retina Today 2012;54-9
24. Saati S, Lo R, Li PY, et al. Mini drug pump for ophthalmic use. Trans Am Ophthalmol Soc 2009;107:60-70
25. Helzner J. New concepts in anti-VEGF delivery. Ophth Manag 2013; Accessed online Nov 20, 2013
26. Clearside Biomedical. Clearside biomedical launched with pipeline and technology focused on drugs delivered to the back of the eye. Available from: http://www.clearsidebio.com/images/newsreleaseclearsideseriesafinancing ledbyhatterasfinal.pdf [Accessed on 20 November 2013]
27. Tetz M, Rizzo S, Augustin AJ. Safety of submacular suprachoroidal drug administration via a microcatheter: retrospective analysis of European treatment results. Ophthalmologica 2012;227:183-9
28. DiPietro C. BCVA improves after intravitreal integrin treatment for wet AMD. OSN Retina 2013;31:30
29. Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009;26:204-10
30. Available from: clinicaltrials. govNCT01397409
31. Available from: clinicaltrials. govNCT01024998
32. Bagley RG, Kurtzberg L, Weber W, et al. sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther 2011;10:404-15
33. Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica 2012;227(Suppl 1):11-20
34. Boehringer backs gene therapy firm Eyevensys. Available from: http://www. pmlive.com/pharma-news/boehringer-backs-gene-therapy-firm- eyevensys-471477 [Accessed on 20 November 2013]
35. Available from: clinicaltrials. govNCT01940900
36. Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica 2009;223:401-10
37. Dugel PU. Anti-platelet derived growth factor: where do we stand? Paper presented at: Retina Subspecialty Day; 9-10 November 2012; Chicago, IL
38. Dugel P. Sirolimus in the treatment of retinal diseases. mTOR inhibitors: a new class of therapeutics. Retina Today 2009;38-41
39. Available from: clinicaltrials. govNCT00766337
40. Available from: clinicaltrials. govNCT01423149
41. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17:16-76 Available from: clinicaltrials. govNCT00767949
42. Kaiser PK, Cruess AF, Bogaert P, et al. Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 2012;250:1563-71